Navigation Links
Discovery Labs Reports Third Quarter 2013 Financial Results
Date:11/12/2013

ed during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of Discovery Labs' products, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals; other risks, including those related to (1) continued compliance with The Nasdaq Capital Market listing requirements, (2) Discovery Labs' efforts to maintain and protect the patents and licenses related to its products, (3) whether it or its strategic partners will be able to attract and retain qualified personnel, (3) other companies' competing products, (3) legal proceedings, and (4) health care reform; and other risks and uncertainties described in Discovery Labs' filings with the Securities and Exchange Commission including the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto.  

Condensed Consolidated Statement of Operations
(in thousands, except per share data)Three Months EndedNine Months EndedSeptember 30,September 30(unaudited)(unaudited)2013201220132012Revenue from collaborative arrangement and grants

$$
8211;$
315$
8211;Operating expenses: (1)Research and development

6,5745,74321,90915,482Selling, general and administrative

4,2994,25512,6489,912Total expenses

10,8739,99834,55725,394Operating loss

(10,813)(9,998)(34,242)(25,394) 

Change in fair value of common stock warrant liability

(1,059)(3,309)1,627(5,063)Interest and other income / (expense), net

(352)(39)(871)(43)Net loss

$
(12,224)$
(13,346)$
(33,486)$
(30,500)Net loss per common share:Basic

$
(0.22)$
(0.31)$
(0.68)$
(0.80)Diluted

$
(0.22)$
(0.31)$
(0.69)$
(0.80)Weighted avg. common shares outstanding:Basic
'/>"/>

SOURCE Discovery Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Novartis: Layoffs as a Sign of Productivity Crisis in R&D; The CBCD Offers New Technology to Aid in Drug Discovery
2. Discovery Labs to Host Conference Call to Discuss Third Quarter 2013 Results on Wednesday, November 13, 2013
3. Global Aptamers Market Technology Trend Analysis Market Report 2013-2018: Therapeutics, Diagnostics, Biosensors, Biomarker/Drug Discovery & Applications
4. Discovery Labs Announces Completion of $50 Million Public Offering
5. Discovery Labs Prices $50 Million Public Offering of Common Stock
6. Discovery Labs Announces Proposed Public Offering of Common Stock
7. Productivity Crisis in Pharmaceutical Industry Increases Drug Prices; The CBCD Offers New Technology to Aid in Drug Discovery
8. Vet-Stem, Inc. Founder and CEO Presents at TargetMeeting’s 3rd World Drug Discovery Online Conference
9. Drug Discovery Using Natural Products - Optimization Studies of Inhibitors of Glucan Synthesis as Anti-Fungal Agents, New Life Science Webinar Hosted by Xtalks
10. Global Biosimulation Technology Market (For Drug Discovery & Development) (2012 - 2017)
11. Discovery Meets Recovery in New Cedars-Sinai’s Advanced Health Sciences Pavilion Designed by HOK
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Varian, Inc.,(NasdaqGS: VARI) announced today the ... (ELSD) for conventional and high speed liquid,chromatography. ... solvent,compatibility, and excellent baseline stability, Varian ELSDs ... detectors for busy pharmaceutical,and analytical laboratories. In ...
... medium and ... large veins, ... ) today announced CE Mark approval of its ACUITY(R),Spiral left ventricular ... pacemakers, both of,which treat heart failure. The product features a spiral ...
... 3 NicOx S.A.,(Euronext Paris: COX) today announced ... the United States, which will assess the blood,pressure ... naproxen,using the Ambulatory Blood Pressure Monitoring (ABPM) technique. ... will together recruit a,total of around 420 osteoarthritis ...
Cached Biology Technology:New Chromatography Detectors From Varian, Inc. Extend the Range of Universal Detection for HPLC and LC/MS 2Boston Scientific Announces European Approval of New Heart Failure Lead 2Boston Scientific Announces European Approval of New Heart Failure Lead 3NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis 2NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis 3NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis 4NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis 5
(Date:12/10/2014)... Dec. 08, 2014 Research and Markets ... of the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration ... as rural banking and upgradation of the driver,s ... in the market. Besides the aforementioned projects, biometrics ...
(Date:12/5/2014)... -- Tute Genomics, a leader in cloud-based solutions for genome ... led by UK-based Eurovestech. Peak Ventures and a number ... "We are at a pivotal time in ... seeks new approaches for the diagnosis, treatment and prevention ... and CEO of Tute Genomics. "One of the main ...
(Date:12/3/2014)... , Dec. 2, 2014 As part ... readers, Inception Technologies is pleased to announce the release ... for customers to collect the workforce data that they ... that have been left by existing readers. Many such ... interface, connectivity and modern technology. Older models force users ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Inception Technologies to Release New Biometric Reader 2
... LANSING, Mich. -- The discovery of a new gene ... molecular factories of the future. A team of ... the discovery of Clumped Chloroplasts a new class ... Proceedings of the National Academy of Sciences . ...
... understand how a bacterial pathogen continues to damage tomatoes despite ... Pseudomonas syringae pv. tomato is the causative agent ... a disease that occurs worldwide and causes severe reduction in ... In the spring of 2010, for example, an ...
... plasticity and aging" team, directed by Jean-Marc Lemaitre, ... de Montpellier 1 and 2), has recently succeeded ... 100). These old cells were reprogrammed in vitro ... rejuvenated and human embryonic stem cells (hESC): cells ...
Cached Biology News:Discovery of new gene could improve efficiency of molecular factories 2Research team unravels tomato pathogen's tricks of the trade 2Research team unravels tomato pathogen's tricks of the trade 3Erasing the signs of aging in cells is now a reality 2Erasing the signs of aging in cells is now a reality 3
FluoSpheres® biotin-labeled microspheres, 1.0 µm, yellow-green fluorescent (505/515) *1% solids*...
chk 1 kinase...
muscle actin (HUC1-1)...
... The Human Neural Stem Cell ... media supplements, which can be used ... expansion of NSCs and the induction ... oligodendrocyte lineages. An antibody panel consisting ...
Biology Products: